Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INCY
INCY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INCY News
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Globenewswire
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Newsfilter
Trump May Announce New Drug Tariffs Soon
Apr 02 2026
seekingalpha
Adagene and Incyte Collaborate on Clinical Study for MSS CRC
Apr 02 2026
Globenewswire
Povorcitinib Shows Significant Efficacy in Hidradenitis Suppurativa Treatment
Mar 28 2026
Newsfilter
Povorcitinib Shows Significant Efficacy in HS Treatment at 54 Weeks
Mar 28 2026
Yahoo Finance
INCYTE: PHASE 3 RESULTS FROM STOP-HS TRIAL DEMONSTRATE SUSTAINED CLINICAL EFFICACY OF POVORCITINIB THROUGH WEEK 54 IN MODERATE TO SEVERE HS PATIENTS
Mar 28 2026
moomoo
Incyte Unveils Latest Data on Povorcitinib at AAD 2026
Mar 20 2026
Newsfilter
Knight Therapeutics Secures New Drug Approval in Brazil
Mar 17 2026
Globenewswire
Knight Therapeutics Submits MINJUVI Supplemental Application for New Indication
Mar 17 2026
Globenewswire
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Mar 12 2026
Barron's
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Mar 12 2026
Barron's
Incyte Receives EU Approval for Zynyz in New Indication
Mar 08 2026
NASDAQ.COM
FDA Rejects Zynyz's Additional Indication Application
Mar 07 2026
seekingalpha
Incyte's Zynyz Drug Receives EU Approval for Rare Cancer
Mar 06 2026
stocktwits
Zynyz Approved by EU for Advanced SCAC Treatment
Mar 06 2026
Newsfilter
Show More News
